Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,958 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

NCT04847453

Conditions
Amyloidosis, Immune System Diseases, Immunoglobulin Light-chain Amyloidosis, +11 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • City of Hope Duarte, California, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +23 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 157 locations
View Trial Details
Active, Not Recruiting

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Southern Cancer Center Mobile, Alabama, United States
  • Arizona Oncology Associates - Tuscon-Rusadill Road Tucson, Arizona, United States
  • TOI - Clinical Research Cerritos, California, United States
  • UCSF Fresno Clovis, California, United States
View all 204 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625

Conditions
Abnormalities, Multiple, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, +31 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • USA Health Strada Patient Care Center Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
View all 228 locations
View Trial Details
Active, Not Recruiting

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +21 more
Locations
  • Alaska Oncology and Hematology ( Site 0037) Anchorage, Alaska, United States
  • Banner MD Anderson Cancer Center ( Site 0040) Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036) Phoenix, Arizona, United States
  • University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008) Aurora, Colorado, United States
View all 108 locations
View Trial Details

Related conditions